iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023
October 30 2023 - 7:00AM
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create
a world where cancer can’t hide by providing clinically proven
AI-powered breast health solutions, today announced that it will
release financial results for the third quarter ended September 30,
2023, after the market close, and host a conference call at 4:30 PM
Eastern Time on Monday, November 13, 2023.
Earnings call details are as follows:
Toll Free: 877-545-0523International: 973-528-0016Participant
Access Code: 381129Webcast:
https://www.webcaster4.com/Webcast/Page/2879/49364
About iCADiCAD, Inc. (NASDAQ: ICAD) is a global
leader on a mission to create a world where cancer can’t hide by
providing clinically proven AI-powered solutions that enable
medical providers to accurately and reliably detect cancer earlier
and improve patient outcomes. Headquartered in Nashua, NH., iCAD’s
industry-leading ProFound Breast Health Suite provides AI-powered
mammography analysis for breast cancer detection, density
assessment and risk evaluation. The ProFound Breast Health Suite is
cleared by the U.S. Food & Drug Administration (FDA) and has
received CE mark and Health Canada licensing. Used by thousands of
providers serving millions of patients, ProFound is available in
over 50 countries. For more information, visit www.icadmed.com.
Forward-Looking StatementsCertain statements
contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements about the expansion of
access to the Company’s products, improvement of performance,
acceleration of adoption, expected benefits of ProFound AI®, the
benefits of the Company’s products, and future prospects for the
Company’s technology platforms and products. Such forward-looking
statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance, or achievements of the Company to be materially
different from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to
achieve business and strategic objectives, the willingness of
patients to undergo mammography screening in light of risks of
potential exposure to Covid-19, whether mammography screening will
be treated as an essential procedure, whether ProFound AI will
improve reading efficiency, improve specificity and sensitivity,
reduce false positives and otherwise prove to be more beneficial
for patients and clinicians, the impact of supply and manufacturing
constraints or difficulties on our ability to fulfill our orders,
uncertainty of future sales levels, to defend itself in litigation
matters, protection of patents and other proprietary rights,
product market acceptance, possible technological obsolescence of
products, increased competition, government regulation, changes in
Medicare or other reimbursement policies, risks relating to our
existing and future debt obligations, competitive factors, the
effects of a decline in the economy or markets served by the
Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place
undue reliance on those forward-looking statements, which speak
only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in
this release. For additional disclosure regarding these and other
risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission,
available on the Investors section of our website at
http://www.icadmed.com and on the SEC’s website at
http://www.sec.gov.
Media Inquiries:pr@icadmed.com
Investor Inquiries:Investor Relationsir@icadmed.com
Icad (NASDAQ:ICAD)
Historical Stock Chart
From Apr 2024 to May 2024
Icad (NASDAQ:ICAD)
Historical Stock Chart
From May 2023 to May 2024